Stop Calling Metformin an Anti-Ageing Drug

I followed the evidence behind one of biohacking’s favourite longevity claims. I found a blood-sugar drug, contradictory human studies and no proof that it extends healthy human life.

Image licensed by Shutterstock

I kept hearing the same claim from biohackers.

Metformin was no longer simply a prescription drug used to manage blood sugar. It had supposedly become an anti-ageing drug by some biohackers.

Take metformin, activate AMPK, suppress mTOR, imitate fasting and perhaps live longer.

The story sounded complete.

But was it?

I am naturally suspicious when a pharmaceutical drug is removed from the condition it was designed to manage and repackaged as something healthy people should take for decades.

Still, I did not want to dismiss metformin merely because it was a drug.

I wanted to investigate the evidence behind the anti-ageing claim.

Had researchers shown that healthy people taking metformin lived longer?

Had a randomised human trial demonstrated that metformin slowed ageing?

Or had biohackers taken evidence about blood-sugar management and stretched it into a much larger longevity promise?

The more I investigated, the less convincing the story became.

I found evidence from people with diabetes being transferred to healthy people.

I found observational associations presented as though they proved causation.

I found animal experiments, molecular pathways and biomarkers being spoken about as if they were completed human lifespan trials.

Then I found the exercise research.

That was where the metformin longevity story stopped making sense.

The Sentence That Made Me Investigate

During an interview with Andrew Huberman, Harvard ageing researcher David Sinclair explained that metformin is given to people with type 2 diabetes to lower their blood sugar.

He then referred to observational evidence suggesting that people with diabetes taking metformin lived longer than people without diabetes.

His conclusion was immediate:

So it’s a longevity drug.

That sentence caught my attention.

How did we move from an observational comparison involving people with diabetes to declaring metformin a longevity drug for healthy people?

Those are not the same claim.

A drug can produce a useful result in a person with impaired glucose regulation without slowing the normal ageing process in someone who does not have that problem.

But in the biohacking world, that distinction disappeared.

Metformin lowered blood sugar. Metformin affected AMPK. Some people with diabetes taking metformin appeared to live longer than certain comparison groups.

Therefore, metformin became an anti-ageing drug.

That conclusion looked far stronger than the evidence underneath it.

Source: Huberman Lab: Dr. David Sinclair, The Biology of Slowing & Reversing Aging

I Traced the Famous Longevity Comparison

One of the studies behind the metformin longevity story was published in 2014.

Researchers examined the medical records of people with type 2 diabetes who began treatment with either metformin or a sulfonylurea. They then compared them with matched people who did not have diabetes.

The study reported that the patients who started metformin had longer survival than their matched non-diabetic controls.

That result sounded extraordinary.

People with diabetes taking metformin appeared to live longer than people who did not have diabetes.

It was easy to see why this study became so popular in longevity discussions.

But this was not a randomised longevity trial.

The researchers did not take healthy people, randomly assign half of them to metformin, follow them through life and discover that metformin extended their survival.

They looked backwards through medical records.

That leaves room for differences between the groups that statistical adjustments may not fully remove. The people prescribed metformin could differ from other patients in disease severity, kidney function, body weight, prescribing history, access to care and many other ways.

The comparison was interesting.

It was not proof that metformin slowed ageing.

Read the 2014 observational study

Then I found a later study that examined the same general question over a much longer period.

Using medical records from Wales, researchers followed more than 129,000 people with type 2 diabetes treated with metformin and compared them with matched non-diabetic controls.

The result changed when the observation period became longer.

During shorter follow-up, metformin users appeared to have a survival advantage. But over the full 20-year period, people with diabetes treated with metformin had shorter survival than the matched controls.

The early longevity advantage did not survive the longer analysis.

Metformin users still survived longer than patients using sulfonylureas, but that only showed that metformin performed better than another diabetes treatment. It did not show that metformin made people live longer than comparable people without diabetes.

This is exactly why observational research must not be converted into a confident anti-ageing prescription.

Change the comparison group, the follow-up period or the statistical method, and the exciting longevity headline may disappear.

Yet the original claim continues to circulate.

Read the 20-year comparison

Managing Blood Sugar Is Not Slowing Ageing

I then looked at the Diabetes Prevention Program, one of the most important human trials involving metformin.

The study included 3,234 people who were overweight or obese and already had impaired glucose regulation. They were at high risk of developing type 2 diabetes.

These were not metabolically healthy adults testing metformin for longevity.

Participants received metformin, an intensive lifestyle intervention or placebo.

Metformin reduced the development of diabetes by 31 per cent compared with placebo.

The lifestyle intervention reduced it by 58 per cent.

The lifestyle programme was substantially more effective than metformin at preventing progression to diabetes.

That is useful information about diabetes prevention.

It is not proof that metformin is an anti-ageing drug.

Preventing a metabolic condition in people who are already at high risk does not demonstrate that a healthy person will age more slowly by taking the same drug.

This sounds obvious when stated plainly.

Yet biohackers repeatedly take results from people with diabetes, prediabetes, obesity or insulin resistance and present them to healthy audiences under the word “longevity.”

The disease disappears from the story.

The drug remains.

Read the Diabetes Prevention Program trial

Then I Found the 21-Year Mortality Results

If metformin genuinely produced a broad longevity effect, I expected that advantage to become visible during long-term follow-up.

The Diabetes Prevention Program Outcomes Study followed participants for a median of approximately 21 years.

Metformin had helped delay the development of diabetes.

But it did not reduce all-cause mortality.

It did not reduce cardiovascular mortality.

It did not reduce cancer mortality.

The researchers stated plainly that although metformin and lifestyle intervention prevented diabetes, neither intervention reduced the three mortality outcomes.

This was a population already at elevated metabolic risk.

There was a real blood-sugar problem for metformin to manage.

Yet after more than two decades, the metformin group did not gain a mortality advantage.

That result should have forced the longevity world to become more careful.

Instead, the discussion often returned to AMPK, mTOR, animal studies and biomarkers.

But none of those things can replace the human outcome that matters.

Did people live longer?

In this long-term randomised follow-up, they did not.

Read the 21-year mortality analysis

The Exercise Study Changed the Entire Investigation

I could already see that the lifespan claim was unproved.

Then I found something more disturbing.

Metformin may interfere with the benefits of exercise.

Exercise is not a theoretical anti-ageing intervention.

It improves cardiovascular fitness, insulin sensitivity, physical function and mitochondrial capacity. It helps preserve the muscle and independence that people commonly lose as they grow older.

Researchers conducted a randomised, double-blind trial involving older adults completing 12 weeks of aerobic exercise training.

Participants received either metformin or placebo.

The researchers expected metformin and exercise to work together.

That is not what happened.

Metformin weakened the improvement in cardiorespiratory fitness.

It reduced the improvement in whole-body insulin sensitivity.

Most importantly for anyone interested in mitochondrial health, metformin prevented the increase in skeletal-muscle mitochondrial respiration produced by exercise.

The exercise was trying to create a beneficial mitochondrial adaptation.

Metformin interfered with it.

The researchers concluded that more work was needed before metformin could be recommended as a drug to promote healthy ageing.

I stopped at that study for a while.

What kind of anti-ageing drug weakens the mitochondrial benefits of exercise?

Biohackers may call metformin’s interference with energy production “hormesis.”

They may say that temporarily stressing mitochondria activates protective pathways.

But using the word hormesis does not prove that continually inhibiting energy production with a prescription drug is beneficial for a healthy person.

The dose matters.

The tissue matters.

The person’s metabolic condition matters.

The duration matters.

And the final human outcome matters.

A pathway explanation cannot erase a human trial showing that exercise adaptations became weaker when metformin was added.

Read the aerobic exercise and mitochondrial adaptation trial

It Also Blunted Muscle Growth

The aerobic exercise study was not alone.

The MASTERS trial examined healthy older adults performing progressive resistance training. Participants received either metformin or placebo in a randomised, double-blind design.

Both groups trained.

Both groups became stronger.

But the people receiving metformin gained less lean body mass and less thigh-muscle mass.

Metformin blunted the hypertrophic response to resistance exercise.

That is not a trivial problem.

Preserving muscle is one of the foundations of healthy ageing.

Muscle supports movement, physical independence, glucose disposal and resilience. Losing it increases vulnerability as people grow older.

Biohackers want to call metformin an anti-ageing drug while dismissing its interference with muscle growth as a small inconvenience.

I do not accept that logic.

When a healthy person is being encouraged to take a prescription drug for an unproved purpose, the burden of proof belongs to the people promoting the drug.

They must prove that its long-term benefits are greater than its interference with exercise, mitochondrial adaptation and muscle growth.

They have not proved that.

Read the MASTERS resistance-training trial

David Sinclair’s Own Routine Exposed the Contradiction

After reading the exercise research, I returned to the conversation between David Sinclair and Andrew Huberman.

This time, the discussion sounded very different.

Sinclair called metformin a longevity drug.

But he also said that he skipped it on days when he planned to exercise.

He explained that metformin reduced stamina because it inhibited the body’s ability to produce energy. According to Sinclair, this could cause someone to perform fewer repetitions during a workout.

He argued that reports about exercise interference had been exaggerated.

Then he said that, in an “abundance of caution,” he still avoided metformin on exercise days.

That contradiction is difficult to ignore.

If the interference is insignificant, why organise your exercise schedule around it?

If this is a reliable anti-ageing treatment, why avoid it before performing one of the most reliable healthy-ageing interventions available?

Sinclair also said that he had stomach sensitivity to metformin and did not take it when he was not feeling well.

He did not say during this interview that he had permanently stopped metformin. It would be inaccurate to claim that he completely abandoned it.

But his own routine still revealed the limitations.

One of metformin’s most visible longevity advocates did not simply take it every day as an uncomplicated anti-ageing intervention.

He skipped it around exercise.

He adjusted his routine because of its effects on stamina and energy production.

He avoided it when his stomach was sensitive.

That is not the clean longevity story presented in headlines.

Listen to the Huberman Lab conversation

Then the Conversation Moved to Berberine

Immediately after discussing metformin’s effects on exercise and Sinclair’s stomach sensitivity, Huberman asked him about berberine as an alternative.

Sinclair said that he had used berberine before he had access to metformin. He also acknowledged that human clinical trials had reported improvements in insulin sensitivity.

That led me to the direct clinical comparison.

In a small randomised pilot trial, 36 adults with newly diagnosed type 2 diabetes received either berberine or metformin for three months.

Berberine lowered HbA1c, fasting glucose and post-meal glucose to a degree similar to metformin.

It also reduced triglycerides and produced additional improvements in lipid measurements.

This was a small study.

It does not prove that berberine is superior to metformin in every patient, and it does not make berberine a proven anti-ageing treatment.

But it exposes how ordinary the central metformin claim really is.

Metformin manages blood sugar.

It is not the only compound capable of doing that.

And blood-sugar management does not become human lifespan extension simply because a Harvard researcher places it inside a longevity conversation.

The same standard must apply to both compounds.

Lower glucose is lower glucose.

It is not proof of slower ageing.

Read the randomised berberine-versus-metformin pilot trial

There Is Also a Long-Term Nutritional Cost

The longer I investigated metformin, the more I realised that its side effects could not be treated as a separate issue.

Long-term metformin use is associated with vitamin B12 depletion.

In the Diabetes Prevention Program Outcomes Study, low or borderline-low vitamin B12 levels were more common among people assigned to metformin.

Each additional year of metformin use was associated with a 13 per cent increase in the odds of vitamin B12 deficiency.

Anaemia was also more common among metformin users, and neuropathy was more prevalent among participants taking metformin who developed low B12.

The usual response is that B12 can be monitored and replaced.

That misses the point.

A side effect may be worth managing when a drug is being used to treat a medical condition.

The calculation changes when a healthy person is taking the drug for a lifespan benefit that has never been demonstrated.

In that situation, B12 depletion is not an acceptable footnote underneath a proven benefit.

It is a documented cost underneath an unproved promise.

Read the long-term vitamin B12 analysis

TAME Does Not Prove Anything Yet

Whenever the missing human evidence becomes impossible to ignore, the conversation eventually reaches TAME, the Targeting Aging with Metformin trial.

Biohackers sometimes mention TAME as if it validates metformin’s anti-ageing status.

It does not.

The purpose of TAME is to test whether metformin can delay the development or progression of major age-related conditions.

The trial exists because that question remains unanswered.

As of July 2026, the official TAME website still described the project as an upcoming six-year programme and said that fundraising was continuing to support its launch.

A future trial is not present evidence.

A proposed hypothesis is not a clinical result.

Researchers planning to test whether metformin affects ageing does not mean that metformin has already been shown to do so.

The research protocol behind a related metformin study makes the uncertainty even clearer.

It states that the human evidence used to support metformin for ageing came from people with type 2 diabetes or other medical conditions, not disease-free subjects.

The protocol also proposes that metformin may reduce insulin sensitivity and mitochondrial function in people who are already insulin-sensitive, while producing different effects in people who are insulin-resistant.

That is not a minor detail.

It means the same drug may behave differently depending on whether the person has the metabolic problem the drug is intended to manage.

Yet biohacking discussions often erase that distinction and treat metformin as a universal longevity tool.

Read the official TAME trial overview

Read the related clinical research protocol

This Is How Evidence Becomes Manipulative

I am not accusing every metformin researcher of manipulating data.

The manipulation usually happens after the study is published.

It happens when:

Each step may sound small.

Together, they transform a blood-sugar drug into an anti-ageing myth.

My Standard Is Higher

I do not trust a pharmaceutical drug as a lifelong anti-ageing strategy merely because it activates AMPK, affects mTOR or produces interesting results in animals.

A drug taken by healthy people for decades must earn that position.

It must show meaningful benefits in healthy people.

It must improve real human outcomes.

It must demonstrate that the benefits outweigh the costs.

And it must prove that people age better, remain healthier or live longer because they take it.

Metformin has not met that standard.

What did I find when I investigated it?

I found a prescription drug that manages blood sugar.

I found an influential observational result that weakened when another study followed patients for longer.

I found a major diabetes-prevention trial in which lifestyle intervention was substantially more effective.

I found 21-year follow-up data showing no reduction in all-cause, cardiovascular or cancer mortality.

I found randomised human trials showing interference with aerobic fitness, mitochondrial respiration and muscle growth.

I found long-term vitamin B12 depletion.

I found one of metformin’s most famous advocates skipping it on exercise days and avoiding it when his stomach was sensitive.

And I found an anti-ageing trial that, as of July 2026, had still not produced the human evidence needed to justify the claim.

That is not a proven longevity drug.

That is a blood-sugar drug surrounded by a longevity story that ran far ahead of the evidence.

Stop calling metformin an anti-ageing drug.

It has never proved that it deserves the name.

Studies and Sources

1. Can People With Type 2 Diabetes Live Longer Than Those Without?

A 2014 observational study reported longer survival among patients beginning metformin than among matched non-diabetic controls. It did not randomly test metformin in healthy people.

2. Comparison of Long-Term Effects of Metformin on Longevity

A later study using up to 20 years of records found that metformin-treated patients had shorter survival than matched non-diabetic controls, although they survived longer than patients using sulfonylureas.

3. Reduction in the Incidence of Type 2 Diabetes With Lifestyle Intervention or Metformin

Lifestyle intervention reduced diabetes incidence by 58 per cent, compared with 31 per cent for metformin, among people already at high risk.

4. Effect of Metformin and Lifestyle Interventions on Mortality

After approximately 21 years, metformin did not reduce all-cause, cardiovascular or cancer mortality.

5. Metformin Inhibits Mitochondrial Adaptations to Aerobic Exercise Training

Metformin weakened improvements in fitness and insulin sensitivity and prevented the exercise-related increase in skeletal-muscle mitochondrial respiration.

6. Metformin Blunts Muscle Hypertrophy in Response to Resistance Training

Older adults taking metformin gained less lean body mass and less thigh-muscle mass during progressive resistance training.

7. Long-Term Metformin Use and Vitamin B12 Deficiency

Long-term exposure was associated with B12 deficiency and anaemia, with the odds of deficiency increasing with each year of use.

8. Efficacy of Berberine in Patients With Type 2 Diabetes Mellitus

In a small randomised pilot trial, berberine produced glucose-lowering effects similar to metformin and also improved several lipid measurements.